AVEO

AVEO Pharmaceuticals Stock Price

5.64
-0.19 (-3.26%)
Upgrade to Real-Time
Afterhours (Closed)
5.64
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
AVEO Pharmaceuticals Inc AVEO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.19 -3.26% 5.64 17:14:05
Close Price Low Price High Price Open Price Previous Close
5.64 5.60 5.88 5.80 5.83
Bid Price Ask Price Spread News
5.60 5.79 0.19 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,486 176,498 $ 5.70 $ 1,006,070 463,930 0.465322 - 13.01
Last Trade Time Type Quantity Stock Price Currency
16:59:42 1 $ 5.79 USD

AVEO Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 145.56M 25.81M 23.20M $ 28.80M $ - -0.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

AVEO Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVEO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.356.385.606.03234,436-0.71-11.18%
1 Month6.116.785.31226.08308,745-0.47-7.69%
3 Months4.466.784.135.49437,5091.1826.46%
6 Months3.9013.013.606.22663,6271.7444.62%
1 Year0.94913.010.4653222.69980,9944.69494.31%
3 Years3.2013.010.4653221.772,291,0322.4476.25%
5 Years1.2613.010.4653221.971,973,0614.38347.62%

AVEO Pharmaceuticals Description

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.


Your Recent History
NASDAQ
AVEO
AVEO Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.